· Executive Brief
World Pneumonia Day 2026
Move from isolated campaign activity to one connected operating plan across internal and community partners.
Leadership signal
Use World Pneumonia Day to examine the system behind the message.
A public-facing observance can involve communications, operations, service lines, community partners, and leadership. Before publishing activity, align the message with real routes, available support, ownership, escalation, and the method used to answer questions that the campaign may generate.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Pneumonia is an operating problem that starts long before admission
Pneumonia reaches a health system through emergency departments, inpatient units, intensive care, nursing homes and primary care at the same time. The people affected are increasingly old. In mainland Portugal, the adult hospitalization rate for community-acquired pneumonia rose from 3.61 to 5.28 per 1000 persons-year between 2000 and 2019.[1] Over the same period, patients older than 80 years grew from 30.4% to 53.1% of those admissions.[1] That shift changes staffing, bed demand and discharge planning, not only clinical care.
The prevention side of the pathway is underused even where services exist. In an intensive care unit at a Japanese tertiary hospital, 77.1% of patients were eligible for pneumococcal vaccination.[4] Yet only 17.1% of eligible patients with assessed status reported vaccination, and 31.7% had unknown status.[4] In an Italian diabetes population, recorded coverage reached only 28.0% by June 2024, a pattern the authors described as compatible with incomplete integration into care pathways.[6]
Risk also continues well after discharge. A multicenter study reported long-term mortality after discharge of 6.3% in its Spanish derivation cohort and 17.4% in a U.S. validation cohort.[3] Nursing home residency was one of the factors in the resulting risk index, which places post-acute partners inside the pneumonia pathway rather than beside it.[3]
World Pneumonia Day is a useful moment for leaders to ask a narrower question than awareness alone. Where does a person who should be protected, treated or followed up fall out of the system, and who owns that step? The sections below add current peer-reviewed evidence on burden, vaccination coverage, delivery models, transitions, equity, workforce and communication. They sit beside the executive guidance already on this page and give boards and operating leaders a shared factual base.
Current evidence
What the research says about burden and the protection gap
Long-run U.S. mortality data show real progress alongside persistent gaps. The national age-adjusted mortality rate for influenza and pneumonia fell from 35.93 per 100,000 residents in 1999 to 16.46 per 100,000 residents in 2023.[2] That is an average annual decline of 3.18%.[2] Adults aged 85 and above had the highest crude death rate.[2] By contrast, the 55 to 64 age group was the only stratum with a statistically meaningful upward trend in crude mortality.[2]
Hospital demand is growing with population aging. In Portugal, the mean age of patients admitted with community-acquired pneumonia rose from 70.1 to 77.7 years, and admissions of patients older than 85 years increased fourfold.[1] Invasive mechanical ventilation was used in 3.1% of episodes in 2000 and 7.5% in 2019, with significant age imbalance.[1] Case fatality declined modestly from 23.1% to 21.8% between 2016 and 2019.[1] Admissions peaked in January, while case fatality was highest in the summer months.[1]
Vaccination coverage in high-risk groups is low across countries and settings. Among adults with chronic respiratory diseases in France, complete primary pneumococcal vaccination between 2013 and 2020 was observed in 16.2%.[5] Influenza coverage in the same population was 56.8% for the 2020–2021 season.[5] Older age predicted influenza vaccination but not pneumococcal vaccination, which was instead associated with having three or more comorbidities and more healthcare visits.[5] A meta-analysis of 51 studies in rheumatic diseases found pooled pneumococcal vaccination rates of 30% to 41% across four conditions.[14]
Where coverage is very low, even partial protection matters. In a matched case-control study across 14 hospitals in Eastern China, five-year PPV23 coverage was 2.14% among cases and 2.76% among controls.[7] The vaccine was associated with a 22.5% reduction in hospitalization for community-acquired pneumonia, with protection concentrated in non-severe disease.[7] Extending the exposure window to six years yielded no significant effect.[7] For executives, the lesson is not vaccine selection, which belongs to clinical governance, but the size of the gap between eligibility and protection.
Taken together, these studies describe a pathway with high and rising demand and a prevention step that most eligible people never complete.[1][5] Because the studies differ by country, population and definition, they support a direction for local measurement rather than an external benchmark.
Figure 1
Most high-risk adults in these studies were not recorded as protected
Percent of the study population with reported or recorded pneumococcal vaccination, as defined in each study. Values are copied from the cited studies [4], [5], [6], [7], [13]; none is estimated.
Data note. These values come from different countries, populations, years and definitions of vaccination, so this is an indirect comparison; the bars show the size of the protection gap, not a ranking of settings.
Limitation. Some values are self-reported and others come from claims or administrative records; the Chinese value is restricted to a five-year window and the French value to a two-dose sequence.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Five-year PPV23 coverage, older adult controls | 2.76% | Controls aged 60 years and older matched to pneumonia cases across 14 hospitals in Eastern China, 2018–2022 | [7] |
| Complete primary vaccination, chronic respiratory disease | 16.2% | Adults with chronic respiratory diseases in France, PCV13 followed by PPSV23 between 2013 and 2020 | [5] |
| Reported vaccination, eligible ICU patients | 17.1% | 124 of 725 eligible ICU patients with assessed status at a tertiary hospital in Japan, 2023–2024 | [4] |
| Coverage among hospital healthcare workers | 20% | Healthcare workers at an Italian university hospital, survey February to June 2024 | [13] |
| Monthly coverage, adults with diabetes | 28% | 77,138 adults with diabetes in one Italian local health authority, June 2024 | [6] |
Continuum of care
Where the pathway breaks between hospital, home and post-acute care
The hospital stay is a reliable touchpoint for prevention, but it is often missed. In a Japanese teaching community hospital, none of 40 eligible patients were vaccinated during hospitalization before a quality improvement project.[9] During the intervention period, 29 of 36 eligible patients (80.6%) were vaccinated, and overall vaccination at discharge rose from 22.4% to 59.5%.[9] The intervention combined resident education, patient materials, vaccination status in admission documentation, discharge checklists and weekly reminders.[9]
Intensive care admissions show the same gap from another angle. Of 725 eligible ICU patients whose status was assessed, 51.2% reported no pneumococcal vaccination.[4] The authors called for more reliable vaccination records and routine opportunities to assess eligibility and history in this population.[4] When status is unknown, the discharge team cannot hand a clear next step to primary care or a post-acute partner.
Post-discharge risk extends well beyond the 30-day window that many programs track. The Long-term Pneumonia Mortality Index draws on age, smoking history, nursing home residency, comorbidity burden, severity scoring, ventilation use and in-hospital cardiovascular events.[3] It showed an area under the curve of 0.82 in derivation and from 0.75 to 0.78 in the German and U.S. validation cohorts.[3] Because it sorts patients into low-, intermediate- and high-risk groups, it can inform which patients a transition team follows most closely, subject to local validation.[3]
Nursing homes are part of the same continuum. A collaboration between community pharmacies and a quality improvement organization ran 68 vaccination clinics across 33 Pennsylvania nursing homes in one year.[8] Nineteen pharmacies gave 4,938 vaccines, including 1,193 pneumococcal doses.[8] The average relative improvement in pneumococcal vaccination among residents after the clinics was 26.3%.[8] For hospital leaders, partner capacity in post-acute settings can close gaps that the hospital cannot reach on its own.
Other respiratory vaccines move through the same handoffs. In the Pennsylvania program, the average relative improvement among residents was 46.3% for influenza vaccines and 41.4% for COVID-19 vaccines.[8] In the ICU study, influenza vaccination was the only factor independently associated with reported pneumococcal vaccination.[4] Respiratory prevention may therefore work best as one bundled transition step rather than separate campaigns owned by different teams. The mortality index cohorts also differed widely, with long-term mortality of 4.4% in a German cohort followed for six months and 3.6% in a COVID-19 pneumonia cohort.[3] Transition teams should calibrate any risk tool against their own population before using it to allocate follow-up.
Figure 3
Why the pathway breaks
People
- Residents and clinicians unsure of current pneumococcal recommendations
- No named role responsible for offering vaccination during visits or stays
- Administrative staff with low awareness and their own vaccination uncertainty
Process
- Vaccination status not captured in admission documentation
- No discharge checklist step for prevention
- Pneumococcal offers tied to influenza season rather than to every eligible contact
Technology
- Vaccination history missing or unknown in the record
- No prompt at predefined healthcare contacts
- No shared view of status across hospital, primary care and nursing homes
Environment
- Ordering, stocking and refrigeration demands of multiple products
- Winter admission peaks that compress discharge time
- Rural communities with higher mortality and fewer access points
Policy
- Increasingly complex adult vaccination schedules
- No agreement with pharmacies or quality improvement partners for post-acute reach
- Transition programs limited to a 30-day window
Measurement
- Coverage not stratified by age, race, rurality or citizenship
- Unknown status counted as missing rather than as a gap
- Long-term post-discharge outcomes not reviewed
Unranked qualitative cause-and-effect diagram for the outcome in the box: Eligible older and high-risk adults leave hospital, clinic and nursing home contacts without a recorded pneumococcal vaccination offer or a clear post-discharge follow-up owner Causes are assembled from the cited literature [1], [2], [3], [4], [6], [8], [9], [12], [13], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Residents and clinicians unsure of current pneumococcal recommendations; No named role responsible for offering vaccination during visits or stays; Administrative staff with low awareness and their own vaccination uncertainty |
| Process | Vaccination status not captured in admission documentation; No discharge checklist step for prevention; Pneumococcal offers tied to influenza season rather than to every eligible contact |
| Technology | Vaccination history missing or unknown in the record; No prompt at predefined healthcare contacts; No shared view of status across hospital, primary care and nursing homes |
| Environment | Ordering, stocking and refrigeration demands of multiple products; Winter admission peaks that compress discharge time; Rural communities with higher mortality and fewer access points |
| Policy | Increasingly complex adult vaccination schedules; No agreement with pharmacies or quality improvement partners for post-acute reach; Transition programs limited to a 30-day window |
| Measurement | Coverage not stratified by age, race, rurality or citizenship; Unknown status counted as missing rather than as a gap; Long-term post-discharge outcomes not reviewed |
Access
Making the protective step easy to reach
Access to pneumococcal vaccination depends heavily on whether the step is offered at the right moment. In an Italian diabetes cohort of 77,138 people, monthly coverage rose from 7.2% in January 2017 to 28.0% in June 2024.[6] Among people newly diagnosed, the estimated cumulative probability of vaccination was 4.4% at one year and 34.8% at seven years.[6] The three-year estimate was 12.6%, with no marked early increase after diagnosis.[6] The largest monthly gains occurred during influenza vaccination seasons, a timing pattern the authors linked to potential missed opportunities.[6]
On-site offers within existing visits can change that pattern quickly. In a French university day hospital, nurses systematically offered vaccination to unvaccinated patients over three weeks.[10] Coverage among the 102 patients analyzed rose from 39% at baseline to 79%.[10] Two-thirds of unvaccinated patients accepted, and 61% of those who accepted completed counseling in less than five minutes.[10] Acceptance was higher among older patients, with an adjusted odds ratio of 1.98 per 10-year increase in age.[10] That time cost is small enough to test within routine clinic flow.
Supply-chain friction also shapes access. In a survey of 500 physicians, nurses and pharmacists in five countries, 94.0% rated logistical hurdles in ordering and stocking as important.[15] Minimal storage requirements mattered to 84.4%, and most agreed that separate pediatric and adult vaccines increase refrigeration needs (90.0%) and stock handling complexity (89.1%).[15] Respondents also agreed that a single vaccine across age groups would reduce the potential for medical errors (96.3%) and improve inventory management (93.0%).[15] Pneumococcal vaccination itself was rated important by 97.6% of respondents for children and 99.2% for adults, which places the main constraint in delivery rather than perceived value.[15]
Staff are themselves a population with access gaps. At an Italian university hospital, pneumococcal vaccination coverage among healthcare workers was 20%, and 82.7% of those vaccinated received the vaccine in the hospital.[13] Among administrative staff, 19% were vaccinated and 43% preferred in-hospital vaccination.[13] For management staff, vaccine safety and effectiveness were significant determinants.[13] Convenience inside the workplace is a lever that leaders control directly, and it tests the same offer process the organization uses for patients.
For health-system leaders, the access question is practical. Which contacts already happen, and which of them can carry an offer without adding a separate visit? The evidence here favors attaching vaccination to admissions, day-unit visits, chronic disease reviews and nursing home rounds, then testing whether the offer reaches people who rarely use other services.
Executive guidance · System route
Connect the day to an accountable system route.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Define the purpose
- Align the entry point
- Coordinate the partner route
- Manage response
- Review the campaign
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Define the purpose
Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise.
Align the entry point
Connect every communication channel to current information and a clearly identified receiving role or team.
Coordinate the partner route
Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Manage response
Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them.
Review the campaign
Compare intended action with local process signals and partner feedback, then document the improvement to carry forward.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Define the purpose | Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise. |
| Align the entry point | Connect every communication channel to current information and a clearly identified receiving role or team. |
| Coordinate the partner route | Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal. |
| Manage response | Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them. |
| Review the campaign | Compare intended action with local process signals and partner feedback, then document the improvement to carry forward. |
Equity and trust
Who the pathway leaves behind
Progress against pneumonia has not been shared evenly. Among 10.1 million U.S. children, rates of all-cause hospitalized pneumonia declined by 51–57% after routine PCV13 implementation across all age groups.[11] Even so, residual disparities persisted among children with comorbidities and in select racial and income groups.[11] The authors concluded that targeted strategies are needed to address these gaps.[11] The analysis drew on a de-identified claims database covering 2007 to 2019, so children outside that claims population were not observed.[11]
Adult mortality data show a similar pattern. Non-Hispanic Black adults bore the heaviest baseline influenza and pneumonia mortality in 1999, at 38.66 per 100,000 population.[2] The same group saw the most marked relative reduction, to 19.01 per 100,000 population by 2023.[2] Mortality ran consistently higher in men than in women, and rural counties kept higher age-adjusted mortality than metropolitan areas in every year studied.[2] Those gaps point to where outreach, transport and partner capacity matter most.
Gaps also vary by diagnosis and background. Among French adults with chronic respiratory diseases, complete primary coverage ranged from 13.5% in pulmonary hypertension to 24.9% in non-CF bronchiectasis.[5] In the Italian diabetes cohort, foreign citizenship was associated with markedly lower pneumococcal vaccination uptake.[6] Age showed the strongest association with uptake, peaking at 60 to 69 years.[6] Associations with sex and comorbidity were more modest, and contextual factors showed limited associations.[6] The authors could not distinguish the mechanisms responsible, which is itself a reminder that most systems lack the data to explain who is missed and why.[6]
Trust and awareness differ inside the workforce as well. In the Italian hospital survey, physicians cited trust in vaccines (25.3%) and self-protection (23.2%) as key motivators, compared with 12.4% among nursing, technical and rehabilitative staff.[13] Recommendation to family members was 90% among medical and specialist professionals and 77% in nursing, technical and rehabilitative groups.[13] An equity review that includes staff can surface the same trust gaps that patients and communities experience.
Equity work depends on stratified data that many organizations do not yet hold in one place. Leaders can ask for coverage, admissions and post-discharge outcomes reported by age, race and ethnicity, geography, language, citizenship and insurance before setting targets. Where unknown status is common, it should be reported as its own category, because missing records often fall hardest on people with the least continuity of care. Community partners such as pharmacies, faith groups and nursing homes can help test whether a gain inside the hospital reaches the neighborhoods with the highest burden.
Human infrastructure
The people who make prevention reliable
The successful programs in this evidence base rely on clear roles and simple workflow supports more than on new technology. The Japanese hospital project trained 15 residents, whose mean knowledge scores improved from 57% to 92%.[9] Their confidence in counseling rose from 2.0 to 4.4 on a five-point scale.[9] Those gains accompanied checklists, documentation changes and weekly reminders rather than education alone.[9]
Nurses and pharmacists can own the offer. The French day-hospital program assigned nurses to identify indications, counsel patients and give the vaccine on site when accepted.[10] The most common reasons for refusal were insufficient knowledge and concerns about side effects, and nearly half of refusals explicitly referred to COVID-19.[10] Acceptance was also far more frequent among men, with an adjusted odds ratio of 15.4 and a very wide confidence interval.[10] Community pharmacists extended reach into post-acute settings in the Pennsylvania nursing home clinics.[8]
Clinician advice needs ongoing attention. In a cross-sectional survey of 13,363 adults aged 60 and older in six Chinese cities, physician recommendation exerted the largest total positive effect on pneumococcal vaccination uptake (β = 0.349).[12] A health system can track how often its own clinicians recommend the vaccine and set that rate beside local coverage data. A falling rate is an early warning that a refresher is due.
Awareness and practice should be reviewed together. The pneumococcal vaccine landscape now includes multiple products that differ in age indications and serotype composition,[15] so a single training session is unlikely to keep every prescriber current. Leaders can pair periodic refreshers with the record prompts and checklists that the stronger programs here relied on.
Recommendation complexity is a workforce burden in its own right. Surveyed professionals favored simpler, single-vaccine strategies across age groups unless separate vaccines offered a clearly substantial coverage advantage.[15] On average, they said a difference of 34.7% in adult-specific invasive pneumococcal disease serotype coverage would justify adding an adult-specific vaccine.[15] Respondents also saw cost savings from a common vaccine at the practice level (85.1%) and the health system level (83.4%).[15] Every added product or schedule brings training, storage and error risk that frontline teams must absorb.
Executive guidance · Operating dashboard
Review reliability, not campaign activity alone.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Message alignment
Do channels and partners communicate one current and appropriately bounded route?
- Candidate local measure
- Content review status, conflicting instructions, corrections, and unresolved questions.
Executive guidance · Signal
Response ownership
Does every campaign-generated request reach an accountable receiver?
- Candidate local measure
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
Executive guidance · Signal
Partner-route reliability
Do participating teams share one current route and understand who owns each dependency?
- Candidate local measure
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Executive guidance · Signal
Action closure
Did leaders complete and verify the improvement selected for the campaign window?
- Candidate local measure
- Assigned action, status, evidence of completion, and post-action review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Message alignment | Executive sponsor and operational lead |
| Response ownership | Operational owner and participating teams |
| Partner-route reliability | Sending and receiving owners |
| Action closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Transfer responsibility with acknowledgment and visibility.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the sending and receiving owners, shared information, current status, and unresolved dependency.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Connect operating signals to accountable executive review.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Message alignment | Do channels and partners communicate one current and appropriately bounded route? | Executive sponsor and operational lead | At campaign launch and close |
| Response ownership | Does every campaign-generated request reach an accountable receiver? | Operational owner and participating teams | At a locally defined cadence |
| Partner-route reliability | Do participating teams share one current route and understand who owns each dependency? | Sending and receiving owners | At a locally defined cadence |
| Action closure | Did leaders complete and verify the improvement selected for the campaign window? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable pneumonia prevention and transition pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Vaccination status captured at admission | Eligible patients leave with unknown or missing status | Nursing and admitting leadership | Share of eligible admissions with documented status |
| Inpatient offer and discharge checklist | Hospital stay passes without a protective step | Hospital medicine and pharmacy leads | Share of eligible inpatients offered and vaccinated before discharge |
| Nurse-led offer in clinics and day units | Routine visits miss eligible patients | Ambulatory nursing director | Coverage before and after the offer, with documented reasons for refusal |
| Post-acute partner agreement | Nursing home residents remain unreached | Post-acute network executive | Clinics held, doses given and partner-reported coverage change |
| Risk-based follow-up after discharge | High-risk patients lose contact after 30 days | Care transitions leader | Follow-up completion by risk group beyond 30 days |
| Staff education and staff vaccination access | Knowledge erodes and staff remain unprotected | Chief nursing and medical officers with occupational health | Training completion and in-house staff coverage |
| Stratified equity review | Gaps by age, race, rurality or citizenship stay hidden | Equity and quality leadership | Coverage and outcomes reported by subgroup at each review |
Control points derived from the cited evidence [4], [6], [8], [9], [10], [11], [13] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
What people need to hear, and who should say it
Many missed vaccinations are communication failures rather than refusals. In the rheumatic disease meta-analysis, the two major reasons for not receiving vaccination were lack of awareness and not being offered vaccination by doctors.[14] A larger proportion of patients received vaccine education from rheumatologists than from general practitioners.[14] Pooled influenza vaccination rates in the same conditions ranged from 42% to 53%, above the corresponding pneumococcal rates.[14] That finding suggests that specialty visits can carry a preventive message when the specialist is expected to deliver it.
Short, direct conversations appear workable. In the day-hospital program, most accepted vaccinations were completed within five minutes of counseling.[10] Refusals often reflected knowledge gaps and side-effect concerns linked to COVID-19, so public messages should anticipate those questions rather than repeat general awareness slogans.[10] Communication teams can prepare plain-language answers to those two concerns and route remaining questions to a clinician who can respond promptly.
Internal audiences need structured information too. In the Italian hospital survey, preferred information sources included courses, webinars and institutional websites.[13] Administrative staff had lower awareness and more hesitancy than healthcare workers, and 24% were unsure of their own vaccination status.[13] Both groups expressed interest in structured educational initiatives.[13] Nonclinical staff are often the first contact for patients and families, so they belong in that education.
Records are part of communication. When approximately one-third of eligible ICU patients have unknown vaccination status, families and clinicians cannot easily answer a basic question about protection.[4] In that study, status came from a structured questionnaire given to patients or family members during the ICU stay.[4] Recorded vaccination in the diabetes cohort was low and delayed, and the authors proposed evaluating systematic assessment at predefined healthcare contacts.[6]
The French chronic respiratory disease study pointed to simplified vaccination schedules, expanded vaccinator roles and systematic integration of vaccination into care pathways.[5] Influenza coverage of 56.8% in that population was below the European target of 75%, so even the better-established program falls short.[5] Those are operational commitments, and they give communication teams something concrete to describe beyond awareness. A World Pneumonia Day message is more credible when the organization can show that it asks, records and follows through.
Executive guidance · 90-day plan
Use 90 days to correct one visible operating barrier.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how World Pneumonia Day communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how World Pneumonia Day communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Pair recognition with a system people can trust.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Connect the message to one usable, measured, and sustained operating change.
Executive action kit · Day observance
Turn World Pneumonia Day into accountable action.
Move from isolated campaign activity to one connected operating plan across internal and community partners.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.
- Define the purpose
- Align the entry point
- Coordinate the partner route
- Manage response
- Review the campaign
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Content review status, conflicting instructions, corrections, and unresolved questions.
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During World Pneumonia Day, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
World Pneumonia Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Oliveira R, Batista D, Lufinha F, Oliveira H, Diniz A, Froes F, et al. Trends in Hospitalization, Case Fatality, and Mortality for Community-Acquired Pneumonia in Portugal over 20 Years. Epidemiologia. 2026;7(5):125. https://doi.org/10.3390/epidemiologia7050125
- 2.Song N, He J, Shuai X, Zhu H, Xia K. Trends in pneumonia mortality among US adults, 1999 to 2023. Medicine. 2026;105(34):e50389. https://doi.org/10.1097/md.0000000000050389
- 3.Méndez R, González-Jiménez P, Latorre A, Piqueras M, Mengot N, Hervás D, et al. The Long-term Pneumonia Mortality Index: an international multicenter derivation and validation study for patients with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine. 2026;212(6):1305-1314. https://doi.org/10.1093/ajrccm/aamag060
- 4.Watanabe T, Nakano H, Motoki M, Wakimoto Y, Ikechi D, Mochizuki M, et al. Pneumococcal vaccination status in critically ill patients: A cross-sectional study. Human Vaccines & Immunotherapeutics. 2026;22(1):2715279. https://doi.org/10.1080/21645515.2026.2715279
- 5.Roche N, Blanchard E, Fernandes J, Grenier B, Raguideau F, Vacheret M, et al. Differences in influenza and pneumococcal vaccination coverage according to chronic respiratory diseases during the COVID-19 pandemic in France: a nationwide cohort study using the French national health data system. Respiratory Medicine and Research. 2026;90:101320. https://doi.org/10.1016/j.resmer.2026.101320
- 6.Lenzi J, Montalti M, Di Valerio Z, Frassineti V, Benetti P, Messina R, et al. Temporal patterns and potential missed opportunities in pneumococcal vaccination among adults with diabetes: A population-based cohort study. Vaccine. 2026;91:129063. https://doi.org/10.1016/j.vaccine.2026.129063
- 7.Yang T, Ying X, Wu X, Shao J, Ye L, Tao Y. Protection and Duration of 23-Valent Pneumococcal Polysaccharide Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older Adults with Low Vaccination Coverage: A Multicenter Matched Case–Control Study in China. Vaccines. 2026;14(7):646. https://doi.org/10.3390/vaccines14070646
- 8.Stawarz S, McGrath S, Coley K. Improving Nursing Home Vaccination Rates: A Collaboration Between Community Pharmacies and a Quality Improvement Organization. Journal for Healthcare Quality. 2026;48(3). https://doi.org/10.1097/jhq.0000000000000516
- 9.Nakahara S, Tsutsumi T, Kurihara M. Improving Pneumococcal Vaccination Rates during Hospitalization via Resident Education Intervention: A Hospital-based Quality Improvement Project in a Teaching Community Hospital. Journal of Community Hospital Internal Medicine Perspectives. 2026;16(4). https://doi.org/10.55729/2000-9666.1627
- 10.Bory O, Verstraeten M, Aslangul E, Michel M. Evaluation of a nurse-led pneumococcal vaccination program in a day hospital. BMC Health Services Research. 2026;26(1):728. https://doi.org/10.1186/s12913-026-14521-2
- 11.Rozenbaum MH, Averin A, Weycker D, Lapidot R, Miles A, Tort MJ, et al. Residual Disparities in US Children Hospitalized Due to All-Cause Pneumonia Following Implementation of Childhood PCV13 in National Immunization Program. Vaccines. 2026;14(8):679. https://doi.org/10.3390/vaccines14080679
- 12.Wang Y, Yuan S, Xie Y, Dai J, Zhu L, Liu G, et al. Physician recommendation and vaccine hesitancy as key drivers of pneumococcal vaccination among older adults in China: a cross-sectional study using policy-stratified structural equation modeling. Expert Review of Vaccines. 2026;25(1):2645379. https://doi.org/10.1080/14760584.2026.2645379
- 13.Congedo G, Mancini R, Pattavina F, Pascucci D, Bruno S, Laurenti P. Knowledge, Attitudes and Perceived Barriers to Pneumococcal Vaccination: A Cross-Sectional Survey Among Healthcare Workers and Administrative Staff at an Italian University Hospital. Vaccines. 2026;14(6):530. https://doi.org/10.3390/vaccines14060530
- 14.Du D, Zeng T, Qin J, Gao L, Xiong J, Luo F, et al. Vaccination coverage of influenza and pneumococcal vaccines in patients with rheumatic diseases: a systematic review and meta-analysis. Rheumatology. 2026;65(8):keag352. https://doi.org/10.1093/rheumatology/keag352
- 15.Vietri JT, Warren SA, Heffler MJ. Practical Considerations Shaping Pneumococcal Vaccine Selection: A Multinational Cross-Sectional Survey of Healthcare Professionals. Infectious Diseases and Therapy. 2026;15(11):3003-3015. https://doi.org/10.1007/s40121-026-01436-y
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Rising community-acquired pneumonia hospitalization, aging of admissions and seasonal pattern | [1] | 2026 | Current evidence | National administrative hospital data from mainland Portugal, 2000 to 2019; may not reflect U.S. case mix or coding. |
| U.S. influenza and pneumonia mortality trends and disparities by age, race, sex and rurality | [2] | 2026 | Current evidence | Death-certificate data for 1999 to 2023; underlying-cause coding and population-level design, not individual risk. |
| Long-term mortality after pneumonia discharge and a risk index for transition planning | [3] | 2026 | Continuum of care | Prediction study; discrimination varied across cohorts and the German cohort had only six months of follow-up; needs local validation. |
| Pneumococcal eligibility, reported vaccination and unknown status among ICU patients | [4] | 2026 | Continuum of care | Single ICU in Japan; self- or family-reported status by questionnaire. |
| Pneumococcal and influenza coverage among adults with chronic respiratory diseases | [5] | 2026 | Current evidence | French claims data; booster doses not captured; coverage definition required a specific two-dose sequence. |
| Low and delayed pneumococcal vaccination and lower uptake with foreign citizenship among adults with diabetes | [6] | 2026 | Access | One Italian local health authority; recorded vaccination only; mechanisms could not be distinguished. |
| PPV23 association with reduced pneumonia hospitalization in a low-coverage setting | [7] | 2026 | Current evidence | Observational case-control design in Eastern China; wide confidence intervals; no effect in severe disease. |
| Pharmacist-led vaccination clinics in nursing homes | [8] | 2026 | Continuum of care | Retrospective descriptive analysis in one state; relative improvement without a comparison group. |
| Inpatient vaccination through resident education and workflow changes | [9] | 2026 | Continuum of care | Single-center before-and-after quality improvement project with small samples. |
| Nurse-led on-site vaccination in a day hospital and reasons for refusal | [10] | 2026 | Access | Retrospective study of 102 patients over three weeks in one French hospital. |
| Residual disparities in pediatric pneumonia hospitalization after PCV13 | [11] | 2026 | Equity and trust | Commercially insured claims population; retrospective before-and-after design. |
| Physician recommendation and vaccine hesitancy as drivers of pneumococcal vaccination uptake | [12] | 2026 | Human infrastructure | Cross-sectional, self-reported survey of older adults in six Chinese cities; associations estimated by structural equation modeling. |
| Pneumococcal coverage, trust and preferences among hospital and administrative staff | [13] | 2026 | Access | Single Italian university hospital; voluntary email survey. |
| Pooled vaccination coverage and reasons for nonvaccination in rheumatic diseases | [14] | 2026 | Public communication | Meta-analysis of 51 heterogeneous studies; geography and treatment explained part of the variation. |
| Operational considerations in pneumococcal vaccine selection among professionals | [15] | 2026 | Human infrastructure | Online survey of 500 professionals in five countries; perceptions rather than observed outcomes. |
About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.